ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ナルブフィン

Nalbuphine

HCID 5311304
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
20594-83-6
標準SMILES
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
InChIKey
NETZHAKZCGBWSS-CEDHKZHLSA-N
分子式
C21H27NO4
平均分子量
357.4 g/mol
単同位体質量
357.19400834

概要

Nalbuphine is an organic heteropentacyclic compound. It has a role as an opioid analgesic and a mu-opioid receptor antagonist. It derives from a hydride of a morphinan.

名称と識別子

優先名称
Nalbuphine
IUPAC
(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
現地名
ナルブフィン
英語名
nalbuphine
分子式
C21H27NO4
分子量
357.45

名称と別名

nalbuphine20594-83-6NalbufinaNalbuphinumIntapanDTXSID8023345L2T84IQI2KN-Cyclobutylmethyl-4,5alpha-epoxy-3,6alpha,14-morphinantriolCHEBI:7454DTXCID103345(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol17-(Cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol
名称をさらに表示
17-(シクロブチルメチル)-4,5α-エポキシモルフィナン-3,6α,14-トリオールナルブフィン17-シクロブチルメチル-4,5α-エポキシモルフィナン-3,6α,14-トリオール(1S,5R,13R,14S,17S)-4-(シクロブチルメチル)-12-オキサ-4-アザペンタシクロ[9.6.1.01,13.05,17.07,18]オクタデカ-7,9,11(18)-トリエン-10,14,17-トリオールC07251NALBUPNINENalbuphinebase2H3]-NalbuphineNaltrexoneImpurity24NETZHAKZCGBWSS-CEDHKZHLSA-NNalbuphine (1.0mg/ml in Acetonitrile)Nalbuphine (base and/or unspecified salts)17-[Cyclobutylmethyl]-4,5α-epoxymorphinan-3,6α,14-triolMorphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5α,6α)- (9CI)
Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5alpha,6alpha)-(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo(9.6.1.0^(1,13).0^(5,17).0^(7,18))octadeca-7,9,11(18)-triene-10,14,17-triol(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-triene-10,14,17-triol(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro(3,2-e)isoquinoline-4a,7,9-triolRefChem:57230(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo(9.6.1.01,13.05,17.07,18)octadeca-7,9,11(18)-triene-10,14,17-triol243-901-6Nalbuphine (INN)

物性

構造計算による物性補完中

XLogP
0.2
極性表面積
73.2 Ų
水素結合供与体数
3
水素結合受容体数
5
回転可能結合数
2
重原子数
26
形式電荷
0
複雑度
597

実験および物理化学的性質

Drugs · 2 件

DEA NFLIS-Drug Category -> Narcotic Analgesics

Pharmaceuticals -> Listed in ZINC15

LogP1.4
Solubility2.09e+00 g/L
Human DrugsPharmaceuticals
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point230 °C (hydrochloride salt)
Physical DescriptionSolid
Dissociation Constants8.71 and 9.96 (hcl form)
Collision Cross Section189.51 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
230.5 ° · 230.5°
沸点
566.6 · 566.6±50.0 °C(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P301+P317, P304+P340, P317, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

TreatmentThe immediate intravenous administration an opiate antagonist such as naloxone or nalmefene is a specific antidote. Oxygen, intravenous fluids, vasopressors and other supportive measures should be used as indicated. (L1712)
Health EffectsMedical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose.
Adverse Effects · 1 件

The most common adverse effects following nalbuphine administration include sedation, sweating, nausea, vomiting, dizziness, vertigo, dry mouth, and headache. Anaphylactic, anaphylactoid, or severe hypersensitivity reactions have been reported in patients receiving nalbuphine, and immediate supportive medical treatment should be provided should they occur.

Exposure RoutesIntravenous. The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.
Toxicity Summary · 2 件

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein BindingNot appreciably bound.
Pharmacodynamics · 1 件

Nalbuphine is a synthetic opioid agonist-antagonist analgesic of the phenanthrene series. Nalbuphine's analgesic potency is essentially equivalent to that of [morphine] on a milligram basis. The opoioid antagonist activity of nalbuphine is about one-fourth to that of [nalorphine] and 10 times to that of [pentazocine]. Nalbuphine by itself has potent opioid antagonist activity at doses equal to or lower than its analgesic dose. When administered following or concurrent with mu agonist opioid analgesics (e.g., morphine, oxymorphone, fentanyl), nalbuphine may partially reverse or block opioid-induced respiratory depression from the mu agonist analgesic. Nalbuphine may precipitate withdrawal in patients dependent on opioid drugs. Nalbuphine should be used with caution in patients who have been receiving mu opioid analgesics on a regular basis.

Mechanism of Action · 1 件

The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor.

Biological Half-LifeThe plasma half-life of nalbuphine is about 5 hours.
Metabolism/MetabolitesHalf Life: The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
FDA Pharmacological Classification · 6 件

L2T84IQI2K

NALBUPHINE

Mechanisms of Action [MoA] - Competitive Opioid Antagonists

関連反応

8 件
反応記録を作成
HRID 39327 の反応式
HRID 39327生成物として
HRID 533702 の反応式
HRID 533702生成物として
HRID 533703 の反応式
HRID 533703反応物として
HRID 1015685 の反応式
HRID 1015685生成物として
HRID 1289465 の反応式
HRID 1289465反応物として
HRID 1289466 の反応式
HRID 1289466反応物として
HRID 1975972 の反応式
HRID 1975972反応物として
HRID 2390904 の反応式
HRID 2390904生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
20594-83-6
PubChem CID
5311304
DTXSID
DTXSID8023345
ChEMBL
CHEMBL895
ChEBI
CHEBI:7454
UNII
L2T84IQI2K
EC Number
243-901-6
Nikkaji
J14.212C
比重(密度)
1.44 · 1.44±0.1 g/cm3(Predicted)
溶解性
soluble in Methanol
外見
Solid
酸解離定数(Pka)
9.39 · 9.39±0.60(Predicted)
色
White

化学的性質

化学的特性Pale Yellow Solid

Signs and Symptoms of Overdose

Receptor studies show that nalbuphine exerts its action via binding to mu, kappa, and delta receptors, but not to sigma receptors. Nalbuphine is primarily a kappa agonist/partial mu antagonist analgesic. The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor.

Signs and SymptomsSymptoms of overdose include primarily sleepiness and mild dysphoria.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

nalbuphine

DILI Negative

Intravenous

DOI:10.1016/j.drudis.2019.09.022

Toxicity DataLD50: 1100 mg/kg (Oral, Dog) (A308)

安全データ

危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

Established Pharmacologic Class [EPC] - Opioid Agonist/Antagonist

Mechanisms of Action [MoA] - Partial Opioid Agonists

Nalbuphine is an Opioid Agonist/Antagonist. The mechanism of action of nalbuphine is as a Competitive Opioid Antagonist and Partial Opioid Agonist.

MeSH Pharmacological ClassificationCompounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS.
Absorption, Distribution and Excretion · 1 件

The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine. Clinical studies show that the duration of analgesic activity of the drug can range from 3 to 6 hours.

Cellular LocationsMembrane
Metabolite PathwaysNalbuphine Action Pathway

用途と製造

Uses · 1 件

Nalbuphine is indicated for the relief of moderate to severe pain. It can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. [Wikipedia]

Use ClassificationPharmaceuticals

応用分野

使用Nalbuphine is a mixed opioid agonist-antagonist. Nalbuphine is an analgesic (narcotic).

上流・下流製品情報

上流原料

シクロブタンカルボニルクロリド水素化リチウムアルミニウム4,5α-エポキシ-3,14-ジヒドロキシモルフィナン-6-オン・塩酸塩6α-Noroxymorpholシクロブチルメチルブロミドナルブホン4,5α-エポキシ-3,14-ジヒドロキシモルフィナン-6-オンシクロブタンカルボアルデヒド

下流製品

NALBUPHINE塩酸ナルブフィン